Ascentage Pharma Group International (AAPG) Common Equity (2022 - 2025)

Ascentage Pharma Group International (AAPG) has reported Common Equity for 4 consecutive years, with $186.7 million the latest figure, recorded in Q4 2025.

• Quarterly Common Equity rose 389.26% year-over-year to $186.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $186.7 million (up 389.26% YoY) and the FY2025 annual result came in at $190.8 million, up 657796.55% from the prior year.
• Common Equity grew to $186.7 million in Q4 2025 per AAPG's latest filing, from $38.2 million in the prior quarter.
• Over the last five years, Common Equity for AAPG reached as high as $186.7 million in Q4 2025 and fell as low as $9.8 million in Q4 2023.
• A 4-year average of $73.0 million and a median of $47.8 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity plunged 82.93% — and 2025, when it surged 389.26%.
• Year by year, Common Equity stood at $57.5 million in 2022, then tumbled by 82.93% to $9.8 million in 2023, then soared by 289.07% to $38.2 million in 2024, then surged by 389.26% to $186.7 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $186.7 million, $38.2 million, and $9.8 million for Q4 2025, Q4 2024, and Q4 2023 respectively.